You just read:

IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström's Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin's Lymphoma

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

Jun 01, 2018, 04:53 ET